Le mode conseil est activé Arrêter
Pour la navigation rapide entre les blocs

Organisation: Emergent Biosolutions
LEI 549300YW6TUOX8BE5103

Nom de l'organisation
Emergent Biosolutions Inc
Nom du pays
États-Unis
Pays d'enregistrement
États-Unis
Secteur économique
Production de médicaments et biotechnologies
Dette obligataire
450 millions USD

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Dernières données pour

Cotations

Requête envoyé
Accès refusé
Envoyer la requête
Les cotations fournis par les fournisseurs d’information sont de nature indicative

Profile

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD).

Récompenses

Actualités

01/05/2024 Emergent Biosolutions: Costs Associated With Exit Or Disposal Activities, Regulation Fd Disclosure, Financial Statements And Exhibits
29/04/2024 Emergent Biosolutions: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
29/04/2024 Emergent Biosolutions: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
23/04/2024 Emergent Biosolutions: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
13/03/2024 S&P Global Ratings downgrades Local Currency LT credit rating of Emergent Biosolutions to "CCC+"
Toutes les actualités de l'organisation

Documents

Etats financiers IFRS / US GAAP

2024
I q ang
2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Actions

Dernières émissions

Montrer tout

Dette obligataire par devise

Montrer tout Cacher

Codes

  • LEI
    549300YW6TUOX8BE5103
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001367644
  • EIN
    14-1902018

Notations de crédit et notations d’ESG

Macroéconomie

Vous devez vous inscrire pour y accéder.